Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis

Psoriatic arthritis (PsA) is a chronic inflammatory disease with heterogeneous musculoskeletal and dermatologic manifestations, leading to significant functional impairment and reduced quality of life. Although targeted therapies such as Janus kinase inhibitors and interleukin-17 inhibitors have demonstrated efficacy in randomized controlled trials, real-world comparative evidence between these treatment strategies remains limited.

This observational cohort study aims to compare the real-world effectiveness and safety of upadacitinib and interleukin-17 inhibitors in patients with PsA over a 24-week follow-up period. By evaluating clinical outcomes under routine clinical practice conditions, this study seeks to provide evidence to support individualized treatment selection in PsA management.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Psoriatic Arthritis Arthritis Arthritis, Psoriatic Bone Diseases Interleukin-17 Inhibitors Joint Diseases Musculoskeletal Diseases Psoriasis Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases Spinal Diseases Spondylarthritis Spondylarthropathies Spondylitis Upadacitinib

Sex eligibility

All sexes

Study type

Observational

Primary location

Peking University First Hospital

Beijing, China

About this study

This is a real-world, observational cohort study conducted at Peking University First Hospital. Adult patients diagnosed with psoriatic arthritis will be enrolled and followed for 24 weeks in routine clinical practice.

Participants will be categorized into two cohorts based on treatment exposure at baseline: patients receiving upadacitinib and patients receiving interleukin-17 inhibitors. Treatment decisions are made by treating physicians according to standard clinical practice and are not influenced by the study protocol.

Clinical assessments will be performed at baseline and during routine follow-up visits within the 24-week observation period. Effectiveness outcomes will be evaluated across musculoskeletal and dermatologic domains, and safety outcomes will be monitored throughout follow-up. This study does not involve experimental interventions.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥ 18 years
Diagnosis of psoriatic arthritis according to established classification criteria
Treatment with upadacitinib or an interleukin-17 inhibitor at baseline
Availability of baseline and follow-up clinical data over 24 weeks

Exclusion criteria

Diagnosis of other inflammatory arthritides
History of malignancy or severe uncontrolled infection
Incomplete clinical data preventing outcome assessment

Treatment and study plan

Primary outcomes

Clinical effectiveness of treatment

Time frame: Baseline to Week 24

Changes in joint and skin disease activity assessed using validated clinical measures during the 24-week follow-up period.

Sponsors and collaborators

Lead sponsor

Peking University First Hospital

Other

Registry information

Official study title

Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis: A Cohort Study

Acronym: UVIPWP

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Feb 4, 2026
Registry last updated: Feb 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed